一种基于纳米粒子的声动疗法可以减少小鼠的Helicobacter pylori感染,而不会破坏肠道微生物群
Tao Liu1,2,3, Shuang Chai1,2,3, Mingyang Li1,2,3
1Hefei National Research Center for Physical Sciences at the Microscale, University of Science and Technology of China, Hefei, Anhui, 230026, China.
Nature communications
|January 29, 2024
概括
一种新型的非抗生素声动疗法使用带有形的纳米颗粒有效治疗Helicobacter pylori感染. 这种方法克服了抗菌素耐药性,并保留了有益的肠道微生物群,与传统的抗生素不同.
科学领域:
- 生物医学工程 生物医学工程
- 微生物学 微生物学
- 纳米技术 纳米技术
背景情况:
- 杆菌感染是一个全球性的健康问题,需要抗生素治疗.
- 目前的疗法面临的挑战是抗菌素耐药性和肠道失生症.
研究的目的:
- 开发一种非抗生素的声动疗法,用于治疗H. pylori感染.
- 评估新疗法的疗效和微生物群影响.
主要方法:
- 开发的双层甲素涂层纳米颗粒 (Ver-PLGA@Lecithin) 装载有脊椎.
- 利用局部超声波暴露用于声动疗法.
- 在感染H. pylori的小鼠模型中评估治疗疗效.
主要成果:
- 莱素通过超声波产生活性氧物种来中和H. pylori毒性因子和非活化细菌.
- 声动力疗法在减少胃部感染方面显示出与标准三重疗法相似的疗效.
- 与抗生素不同,这种疗法不会破坏肠道微生物群,促进乳酸菌的生长.
结论:
- 声动力学疗法为H. pylori提供了一种有希望的抗生素替代方案.
- 这种方法减轻了抗菌素耐药性,并保持了肠道微生物群平衡.
相关概念视频
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
407
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
407
Peptic Ulcer Disease IV: Management
93
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
93
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
430
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
430
Peptic Ulcer Disease I: Introduction
168
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
168
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
437
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
437
What is Monogastric Digestion?
71.2K
The human body contains a monogastric digestive system. In a monogastric digestive system, the stomach only contains one chamber in which it digests food. Several other animal species also have monogastric digestive systems, including pigs, horses, dogs, and birds. This chapter, however, focuses on the human digestive system.
71.2K


